Ghana's Independent Hemp and Cannabis News Authority - Est. 2026
ACCRA, GHANA · EST. 2026
VERIFIED AND SOURCED
MARCH 2026
VERIFIED AND SOURCED
MARCH 2026
All developments from the Ministry of Interior, NACOC, Parliament, and industry - verified and sourced from official publications.
Hon. Muntaka Mohammed-Mubarak officially declared Ghana's Cannabis Regulatory Programme open on February 26, 2026. Activities restricted to cannabis with THC 0.3% or less under Act 1100 and L.I. 2475.
"This initiative is not about legalising recreational wee but about building a world-class, Ghanaian-led industrial hemp and therapeutic cannabis sector."
- Hon. Muntaka Mohammed-Mubarak, Feb 26, 2026
A Techiman farmer filed a constitutional challenge arguing fee structures are prohibitively high under Articles 17, 174, and 296 of Ghana's 1992 Constitution.
The Chamber of Cannabis Industry Ghana says the sector could generate at least US$1 billion annually - over GH₳12 billion. 1,000 plus industry enquiries received.
Ghana is actively courting Czech institutions ahead of planned 2026 trade missions targeting European capital, technology transfer, and research collaboration.
NACOC states clearly that no individual or company is authorized to issue or facilitate cannabis licences. Apply only at portal.ncc.gov.gh directly.
CED Clinical describes Ghana's programme as a regulatory milestone for West Africa enabling population-specific clinical data from sub-Saharan African cohorts.
Ghana's year-round sunshine and lower production costs versus greenhouse-dependent northern climates are drawing strong North American investment interest.
Parliament passed Act 1019 in 2020, the Supreme Court invalidated Section 43 in 2023, then Act 1100 restored it. Full legal timeline explained.
Beyond CBD, Ghana's framework supports textiles, paper, biodegradable plastics, biofuels, animal feed, hempcrete, and cannabinoid pharmaceuticals.
NACOC continues large-scale enforcement against high-THC cannabis cultivation. The new regulations do not decriminalise recreational use.
Under the R and D licence category, researchers will target CBD therapies for chronic pain, epilepsy, neuropathy, and chemotherapy side effects.